ICCM - רווח נקי למניה (EPS TTM) IceCure Medical, Ltd.
Global distribution in the US and EU mitigates regional Israeli risks. The current trailing twelve-month EPS captures this trend, where -6.55 represents the latest level. Physician training and partnerships with oncologists are facilitating the adoption of cryoablation. However, high marketing expenses and capital burn are hindering IceCure Medical Ltd (ICCM) from achieving stable profitability.
ICCM (IceCure Medical, Ltd.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The long-term reliability of IceCure Medical Ltd (ICCM) is determined by its ability to monetize innovations in cryoablation. This metric calculates the portion of net profit attributable to a single common share per year. By analyzing the annual earnings per share, an investor can see the real efficiency of capital without the interference of issuance noise. The high cost of equipment allows the company to increase this result. A stable trend confirms the resilience of the business model.
